Pharmacogenomics, honestly: what CPIC can and can’t tell you

Your genes really do change how you respond to some medications. They also get oversold constantly. Here’s where the line actually sits.

Pharmacogenomics (PGx) is one of the few areas of consumer genetics with genuine clinical weight. The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes guidelines linking specific genotypes to drug response, for example, that certain CYP2C19 or VKORC1 results should change how a clinician approaches clopidogrel or warfarin.

That’s real, and it’s why we grade these findings highly. But two honest caveats matter. First, a consumer genotyping array is not a clinical test, it reads a limited set of positions and can make errors, so anything important needs confirmation in an accredited lab. Second, a genotype is context, not an instruction. It never tells you to change a dose.

Our hard rule

Every PGx result in Verinome carries the same line: do not start, stop, or change any medication based on this. Bring it to your prescriber, who can weigh your full clinical picture and order proper testing. We’ll tell you what the science says; we won’t pretend to be your doctor.

See what graded results look like.